title: A phase II study of 9-aminocamptothecin in patients with refractory breast cancer.
abstract: We evaluated 9-aminocamptothecin (9-AC) in patients with metastatic or locally recurrent breast cancer who were no longer responsive to standard therapy. Patients were treated with 9-AC with a 72-hr continuous infusion given at a dose of 45 micrograms/m2/hr every 2 weeks. Granulocyte colony-stimulating factor 5 micrograms/kg was given subcutaneously for 7-10 days after completion of the treatment. Eighteen patients were treated, with all patients assessable for toxicity and 15 patients assessable for response. There were two partial responses seen in the 15 patients lasting 3.5 and 5 months, respectively. The major toxicity seen was myelosuppression, with 12 patients having grade 3 or greater granulocytopenia with four episodes of significant infectious complications. In addition, significant thrombocytopenia was seen in 14 patients. The other complications commonly seen were nausea and vomiting and alopecia. 9-AC given as a 3-day continuous infusion has limited activity in previously treated metastatic and locally recurrent breast cancer.
authors.affiliation: Ohio State University Medical Center, Arthur G. James Cancer Hospital and Research Institute, Columbus, USA.
authors.forename: E H
authors.initials: EH
authors.lastname: Kraut
authors.forename: S P
authors.initials: SP
authors.lastname: Balcerzak
authors.forename: D
authors.initials: D
authors.lastname: Young
authors.forename: M A
authors.initials: MA
authors.lastname: O'Rourke
authors.forename: J J
authors.initials: JJ
authors.lastname: Petrus
authors.forename: J P
authors.initials: JP
authors.lastname: Kuebler
authors.forename: D G
authors.initials: DG
authors.lastname: Mayernik
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C080125:9-aminocamptothecin; D002166:Camptothecin